SEATTLE, June 2, 2012 /PRNewswire/ - Oncothyreon Inc.

CHICAGO, June 2, 2012 /PRNewswire/ -- Results observed from pre-specified interim analyses of the randomized, placebo-controlled Phase 3 study, COU-AA-302, demonstrated that

Cabazitaxel (trade name: Jevtana®) has been approved since March 2011 in men with metastatic prostate cancer who no longer respond to conventional therapy with hormone blockers and have already been pre-treated with the cytostatic drug docetaxel.

Interim analysis (IA) results of COU-AA-302, a randomized, phase 3 study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (Abstract LBA 4518)Clinical Science Symposium: New Paradigms for Hormone Therapy in Prostate Cancer, Saturday, June 2, 8:00 - 8:15 a.m., E. Arie Crown TheaterLead Author:

NEW ORLEANS, May 3, 2012 /PRNewswire-FirstCall/ -- ICU Medical, Inc.